We read the excellent Review by Guo-Ping Shi et al. (Mast cells in human and experimental cardiometabolic diseases. Nat. Rev. Cardiol. 12, 643-658; 2015) 1 with great interest. The authors proposed a role for neuropeptides in the activation of cardiac and coronary mast cells, with a specific focus on the role of substance P in these processes. The authors suggest an association between cardiovascular events and allergies. We are interested in basic mechanisms mediating itch. Indeed, a role for substance P and neuropeptides and their interaction with mast cells in the context of itch, allergy, and inflammatory skin disease is paral lel to cardiometabolic events. On the basis of previous studies 2 , the authors conclude that substance P activates mast cells via its cognate receptor, neurokinin 1 (NK-1R; also known as tachykinin receptor 1), to induce mast cell degranulation and subsequent inflammation. We respectfully disagree with involvement of NK-1R in substance P-induced mast cell degranulation. A plethora of studies have demonstrated that substance P-induced mast cell degranu lation and inflammatory properties are mediated via a member of the Mas-related G-protein coupled receptors (MRGPRs), MRGPRX2 NK-1R antagonists have long been investigated for treating inflammatory conditions associated with mast cells, such as migraine and asthma. Despite promising preclinical results in animal models, NK-1R antagonists were ineffective in clinical trials of inflammatory diseases 6, 7 . Given that substance P-induced mast cell degranulation is mediated via MRGPRs, and NK-1R antagonists inhibit mouse Mrgprb2, but not human MRGPRX2, the inefficacy of NK-1R antagonists in treating mast-cell-associated inflammation is no longer a surprise.
Our Correspondence has several implications for future studies in the field of cardiology, for elucidating the role of neuropeptides and mast cells, and for identification of new drug targets in this field. First, the antiinflammatory effects of NK-1R antagonists in animal models of cardiac disease are not predictive of their efficacy in humans. Second, MRGPRX2, a receptor implicated in itch 4, 8 but, to our knowledge, not in any cardiac disease, is mediating substance P-induced mast cell degranulation and might be contrib uting to pathogenesis of various cardiometabolic disorders. Third, given the pivotal role of MRGPRX2 in itch 4, 5, 8 
